Literature DB >> 25546778

Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation.

I Schwab1, F Nimmerjahn.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25546778      PMCID： PMC4285507          DOI： 10.1111/cei.12527

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  23 in total

1.  Reply to Crispin et al.: Molecular model that accounts for the biological and physical properties of sialylated Fc.

Authors:  Peter Sondermann; Andrew Pincetic; Jad Maamary; Katja Lammens; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-17       Impact factor: 11.205

2.  T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies.

Authors:  Constanze Hess; André Winkler; Alexandra K Lorenz; Vivien Holecska; Véronique Blanchard; Susanne Eiglmeier; Anna-Lena Schoen; Josephine Bitterling; Alexander D Stoehr; Dominique Petzold; Tim Schommartz; Maria M M Mertes; Carolin T Schoen; Ben Tiburzy; Anne Herrmann; Jörg Köhl; Rudolf A Manz; Michael P Madaio; Markus Berger; Hedda Wardemann; Marc Ehlers
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

3.  Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.

Authors:  Ian K Campbell; Sylvia Miescher; Donald R Branch; Patrick J Mott; Alan H Lazarus; Dongji Han; Eugene Maraskovsky; Adrian W Zuercher; Anton Neschadim; Danila Leontyev; Brent S McKenzie; Fabian Käsermann
Journal:  J Immunol       Date:  2014-04-23       Impact factor: 5.422

Review 4.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

5.  Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo.

Authors:  Inessa Schwab; Sidonia Mihai; Michaela Seeling; Michael Kasperkiewicz; Ralf J Ludwig; Falk Nimmerjahn
Journal:  Eur J Immunol       Date:  2014-03-07       Impact factor: 5.532

6.  Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.

Authors:  Danila Leontyev; Yulia Katsman; Xue-Zhong Ma; Sylvia Miescher; Fabian Käsermann; Donald R Branch
Journal:  Transfusion       Date:  2012-01-18       Impact factor: 3.157

7.  Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells.

Authors:  Amir H Massoud; Madelaine Yona; Di Xue; Fazila Chouiali; Haydar Alturaihi; Aidan Ablona; Walid Mourad; Ciriaco A Piccirillo; Bruce D Mazer
Journal:  J Allergy Clin Immunol       Date:  2013-11-08       Impact factor: 10.793

8.  B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.

Authors:  Inessa Schwab; Michaela Seeling; Markus Biburger; Susanne Aschermann; Lars Nitschke; Falk Nimmerjahn
Journal:  Eur J Immunol       Date:  2012-10-16       Impact factor: 5.532

9.  Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists.

Authors:  Alice E Wiedeman; Deanna M Santer; Wei Yan; Sylvia Miescher; Fabian Käsermann; Keith B Elkon
Journal:  Arthritis Rheum       Date:  2013-10

10.  Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G.

Authors:  Shohei Ogata; Chisato Shimizu; Alessandra Franco; Ranim Touma; John T Kanegaye; Biswa P Choudhury; Natasha N Naidu; Yutaka Kanda; Long T Hoang; Martin L Hibberd; Adriana H Tremoulet; Ajit Varki; Jane C Burns
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240
View more
  14 in total

Review 1.  Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation.

Authors:  Yusuke Mimura; Radka Saldova; Yuka Mimura-Kimura; Pauline M Rudd; Roy Jefferis
Journal:  Exp Suppl       Date:  2021

2.  Recombinant Proteins and Monoclonal Antibodies.

Authors:  Roy Jefferis
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

3.  N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury.

Authors:  Rhea Bhargava; Kayaho Maeda; Maria G Tsokos; Martha Pavlakis; Isaac E Stillman; George C Tsokos
Journal:  Am J Transplant       Date:  2020-07-06       Impact factor: 8.086

4.  Generation and Comparative Kinetic Analysis of New Glycosynthase Mutants from Streptococcus pyogenes Endoglycosidases for Antibody Glycoengineering.

Authors:  Xin Tong; Tiezheng Li; Chao Li; Lai-Xi Wang
Journal:  Biochemistry       Date:  2018-08-22       Impact factor: 3.162

5.  Site-specific immobilization of endoglycosidases for streamlined chemoenzymatic glycan remodeling of antibodies.

Authors:  Tiezheng Li; Chao Li; David N Quan; William E Bentley; Lai-Xi Wang
Journal:  Carbohydr Res       Date:  2018-02-15       Impact factor: 2.104

6.  IgG1 Fc N-glycan galactosylation as a biomarker for immune activation.

Authors:  Sanne E de Jong; Maurice H J Selman; Ayola A Adegnika; Abena S Amoah; Elly van Riet; Yvonne C M Kruize; John G Raynes; Alejandro Rodriguez; Daniel Boakye; Erika von Mutius; André C Knulst; Jon Genuneit; Philip J Cooper; Cornelis H Hokke; Manfred Wuhrer; Maria Yazdanbakhsh
Journal:  Sci Rep       Date:  2016-06-16       Impact factor: 4.379

7.  Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection.

Authors:  Steven Rockman; Sue Lowther; Sarina Camuglia; Kirsten Vandenberg; Shirley Taylor; Lou Fabri; Sylvia Miescher; Martin Pearse; Deborah Middleton; Stephen J Kent; Darryl Maher
Journal:  EBioMedicine       Date:  2017-04-06       Impact factor: 8.143

Review 8.  Human plasma protein N-glycosylation.

Authors:  Florent Clerc; Karli R Reiding; Bas C Jansen; Guinevere S M Kammeijer; Albert Bondt; Manfred Wuhrer
Journal:  Glycoconj J       Date:  2015-11-10       Impact factor: 2.916

9.  Immunoglobulin Infusion as Therapy Against Influenza?

Authors:  Anke Huckriede
Journal:  EBioMedicine       Date:  2017-04-13       Impact factor: 8.143

10.  Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions.

Authors:  Tania F Rowley; Shirley J Peters; Mike Aylott; Robert Griffin; Nicola L Davies; Louise J Healy; Rona M Cutler; Alison Eddleston; Thomas L Pither; Joshua M Sopp; Oliver Zaccheo; Gianluca Fossati; Katharine Cain; Andrew M Ventom; Hanna Hailu; Eleanor J Ward; John Sherington; Frank R Brennan; Farnaz Fallah-Arani; David P Humphreys
Journal:  Commun Biol       Date:  2018-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.